|Bid||193.09 x 1100|
|Ask||193.07 x 1300|
|Day's Range||184.58 - 196.33|
|52 Week Range||106.65 - 202.76|
|Beta (5Y Monthly)||1.48|
|PE Ratio (TTM)||49.52|
|Earnings Date||Apr 27, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||214.75|
BATON ROUGE, La., Feb. 25, 2020 -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B..
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Last week, you might have seen that Amedisys, Inc. (NASDAQ:AMED) released its full-year result to the market. The...
Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.
Futures: Enphase, Amedisys, 10X Genomics, Palomar were earnings movers overnight. Earlier, AMD showed why investors should focus on the best stocks from the best groups.
BATON ROUGE, La., Feb. 18, 2020 -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three month period and year ended December 31, 2019. Three.
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
Amedisys, Inc. (AMED), announced today that it will report results for the fourth quarter and year ended December 31, 2019, after the market closes on February 18, 2020. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on February 19, 2020. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll).
Zacks.com featured highlights include: Gibraltar Industries, Amedisys, Chevron, MDU Resources and Chemed
With the Q4 reporting cycle gaining pace slowly, investors should look for stocks that are less debt-ridden compared to others instead of considering earnings growth only.
The Zacks Analyst Blog Highlights: Enphase Energy, Brookfield Business Partners, Amedisys, Pure Storage and Match Group
Historically, during the Year of the Rat, the S&P 500's performance has been slightly better than the than the index's overall average of 11.4%.
The Zacks Analyst Blog Highlights: MagnaChip Semiconductor, Ichor, Chico's FAS, Amedisys and PBF Logistics
Zacks.com featured highlights include: SYNNEX, MagnaChip Semiconductor, Delta Air Lines, Amedisys and Forterra